Overview
MAZE market data
Price History
MAZE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.05 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.10 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $12.81 – $53.65 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.6K · P/B 5.62.
Company news
8-K filing — Maze Therapeutics, Inc. (MAZE)SEC EDGAR · May 22, 2026, 9:24 PM
Maze Therapeutics Q1 EPS $(0.45) Beats $(0.56) Estimate, Sales $20.000M Beat $9.286M EstimateBenzinga · May 12, 2026, 8:35 PM
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 FinancialsThe Motley Fool · May 7, 2026, 1:05 PM